Drug Profile


Alternative Names: CV-MG-01; Myasterix

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator CuraVac
  • Class Peptides
  • Mechanism of Action Acetylcholine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myasthenia gravis

Most Recent Events

  • 29 May 2017 CuraVac plans a phase II/III trial for Myasthenia gravis in Belgium and Netherlands (NCT03165435)
  • 01 Nov 2015 Phase-I clinical trials in Myasthenia gravis in Belgium (SC)
  • 01 Jan 2011 CVMG 01 receives Orphan Drug status for Myasthenia gravis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top